期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 60, 期 8, 页码 1127-1135出版社
SPRINGER
DOI: 10.1007/s00262-011-0985-7
关键词
Cancer; Immunotherapy; Progress; Epidemiology; Immunoediting; Evasion
资金
- Medical Research Council [G9721629, G0900950] Funding Source: Medline
- MRC [G0900950, G9721629] Funding Source: UKRI
- Medical Research Council [G9721629, G0900950, G0900950B, G9721629B] Funding Source: researchfish
Although cancer immunology has made vigorous progress over the last decade, its future remains uncertain. Tumors have clearly proved subject to immune surveillance, leading to antigenic editing, and means of activating both T and B arms of the immune system have been devised. Therapeutic vaccination and monoclonal antibody therapy have so far proved disappointing, because tumors prove adept at evasion from immune control. Dual targeting could well counteract evasion, provided that the two targets are independent and are attacked simultaneously. This stage has nearly but not quite been reached in several forms of immunotherapy, particularly of B-cell cancers, although such treatment also carries hazards.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据